Oncology Drug Pipeline Update 2006

Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have allowed the biotechnology industry to deliver on the promise of targeted cancer drugs. However, these three successful drugs are just the top of an emerging line of therapy. Given the fact that they all target tyrosine kinases and that kinase mutations can cause patients to become resistant to these drugs, there is plenty of room for more competition.

Today, there are more than 100 companies developing more than 180 protein kinase inhibitory drugs in more than 300 clinical trials targeting around 40 different cancer indications. The number of protein kinase targets has increased to over 50 different molecular targets in just a few years.

For a complete index of this report visit the source link cited below



Posted by: Janet    Source